Drugs, ISSN 0012-6667, 04/2016, Volume 76, Issue 5, pp. 533 - 549
In the antiretroviral therapy (ART) era, serious non-AIDS events (SNAEs) have become the major causes of morbidity and mortality in HIV-infected persons. Early...
C-REACTIVE PROTEIN | SUSTAINED VIROLOGICAL RESPONSE | INDIVIDUAL PARTICIPANT METAANALYSIS | ACTIVE ANTIRETROVIRAL THERAPY | T-CELL-ACTIVATION | PHARMACOLOGY & PHARMACY | TOXICOLOGY | PLACEBO-CONTROLLED TRIAL | HUMAN-IMMUNODEFICIENCY-VIRUS | CORONARY-HEART-DISEASE | HEPATITIS-C | TISSUE FACTOR EXPRESSION | HIV-1 - drug effects | Humans | Inflammation - immunology | Acquired Immunodeficiency Syndrome - drug therapy | Randomized Controlled Trials as Topic | Acquired Immunodeficiency Syndrome - immunology | HIV Infections - immunology | Clinical Trials, Phase III as Topic | HIV-1 - immunology | Inflammation - drug therapy | Lymphocyte Activation - drug effects | Anti-HIV Agents - therapeutic use | HIV Infections - drug therapy | Antiretroviral Therapy, Highly Active - methods
C-REACTIVE PROTEIN | SUSTAINED VIROLOGICAL RESPONSE | INDIVIDUAL PARTICIPANT METAANALYSIS | ACTIVE ANTIRETROVIRAL THERAPY | T-CELL-ACTIVATION | PHARMACOLOGY & PHARMACY | TOXICOLOGY | PLACEBO-CONTROLLED TRIAL | HUMAN-IMMUNODEFICIENCY-VIRUS | CORONARY-HEART-DISEASE | HEPATITIS-C | TISSUE FACTOR EXPRESSION | HIV-1 - drug effects | Humans | Inflammation - immunology | Acquired Immunodeficiency Syndrome - drug therapy | Randomized Controlled Trials as Topic | Acquired Immunodeficiency Syndrome - immunology | HIV Infections - immunology | Clinical Trials, Phase III as Topic | HIV-1 - immunology | Inflammation - drug therapy | Lymphocyte Activation - drug effects | Anti-HIV Agents - therapeutic use | HIV Infections - drug therapy | Antiretroviral Therapy, Highly Active - methods
Journal Article
The Journal of Infectious Diseases, ISSN 0022-1899, 3/2011, Volume 203, Issue 6, pp. 780 - 790
Background. Chronic human immunodeficiency virus (HIV) infection is associated with intestinal permeability and microbial translocation that contributes to...
T lymphocytes | HIV/AIDS | HIV infections | Enterocytes | HIV | RNA | Mortality | Ribosomal DNA | AIDS | Biological markers | Operating rooms | VIRAL LOAD | INFECTIOUS DISEASES | GASTROINTESTINAL-TRACT | ENDOTOXIN | MICROBIOLOGY | IMMUNOLOGY | ACTIVE ANTIRETROVIRAL THERAPY | T-CELL-ACTIVATION | DISEASE | IMMUNE ACTIVATION | LIPOPOLYSACCHARIDE | MICROBIAL TRANSLOCATION | EXPRESSION | HIV Infections - blood | Humans | Middle Aged | Logistic Models | Male | Biomarkers - blood | Case-Control Studies | Cause of Death | Lipopolysaccharide Receptors - blood | Young Adult | Lipopolysaccharides - blood | RNA, Viral | Fatty Acid-Binding Proteins - blood | Adult | HIV Infections - mortality | CD4-Positive T-Lymphocytes | Natural immunity | Immune response | Research | HIV infection | Patient outcomes | Major and Brief Reports
T lymphocytes | HIV/AIDS | HIV infections | Enterocytes | HIV | RNA | Mortality | Ribosomal DNA | AIDS | Biological markers | Operating rooms | VIRAL LOAD | INFECTIOUS DISEASES | GASTROINTESTINAL-TRACT | ENDOTOXIN | MICROBIOLOGY | IMMUNOLOGY | ACTIVE ANTIRETROVIRAL THERAPY | T-CELL-ACTIVATION | DISEASE | IMMUNE ACTIVATION | LIPOPOLYSACCHARIDE | MICROBIAL TRANSLOCATION | EXPRESSION | HIV Infections - blood | Humans | Middle Aged | Logistic Models | Male | Biomarkers - blood | Case-Control Studies | Cause of Death | Lipopolysaccharide Receptors - blood | Young Adult | Lipopolysaccharides - blood | RNA, Viral | Fatty Acid-Binding Proteins - blood | Adult | HIV Infections - mortality | CD4-Positive T-Lymphocytes | Natural immunity | Immune response | Research | HIV infection | Patient outcomes | Major and Brief Reports
Journal Article
3.
Full Text
Immune reconstitution inflammatory syndrome: The trouble with immunity when you had none
Nature Reviews Microbiology, ISSN 1740-1526, 02/2012, Volume 10, Issue 2, pp. 150 - 156
Some individuals who are infected with HIV rapidly deteriorate shortly after starting antiretroviral therapy, despite effective viral suppression. This...
MYCOBACTERIUM-TUBERCULOSIS | PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY | ORGAN TRANSPLANT RECIPIENTS | RISK-FACTORS | PNEUMOCYSTIS-CARINII-PNEUMONIA | CD4(+) T-CELLS | MICROBIOLOGY | ANTIRETROVIRAL THERAPY | RESTORATION DISEASE | HOMEOSTATIC PROLIFERATION | HIV-INFECTED PATIENTS | Antibodies, Monoclonal, Humanized - adverse effects | Immune Reconstitution Inflammatory Syndrome - etiology | Antibodies, Monoclonal, Humanized - therapeutic use | Natalizumab | Immune Reconstitution Inflammatory Syndrome - immunology | AIDS-Related Opportunistic Infections - immunology | Humans | Risk Factors | HIV Infections - immunology | Immunity, Innate - immunology | Models, Immunological | Animals | Immune Tolerance - immunology | Immunity, Innate - physiology | Multiple Sclerosis - immunology | HIV Infections - drug therapy | Lymphopenia - immunology | Mice | Disease Models, Animal | Multiple Sclerosis - drug therapy | Immunotherapy | Physiological aspects | Development and progression | Inflammation | Research | T cells | Health aspects | HIV infection | Risk factors
MYCOBACTERIUM-TUBERCULOSIS | PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY | ORGAN TRANSPLANT RECIPIENTS | RISK-FACTORS | PNEUMOCYSTIS-CARINII-PNEUMONIA | CD4(+) T-CELLS | MICROBIOLOGY | ANTIRETROVIRAL THERAPY | RESTORATION DISEASE | HOMEOSTATIC PROLIFERATION | HIV-INFECTED PATIENTS | Antibodies, Monoclonal, Humanized - adverse effects | Immune Reconstitution Inflammatory Syndrome - etiology | Antibodies, Monoclonal, Humanized - therapeutic use | Natalizumab | Immune Reconstitution Inflammatory Syndrome - immunology | AIDS-Related Opportunistic Infections - immunology | Humans | Risk Factors | HIV Infections - immunology | Immunity, Innate - immunology | Models, Immunological | Animals | Immune Tolerance - immunology | Immunity, Innate - physiology | Multiple Sclerosis - immunology | HIV Infections - drug therapy | Lymphopenia - immunology | Mice | Disease Models, Animal | Multiple Sclerosis - drug therapy | Immunotherapy | Physiological aspects | Development and progression | Inflammation | Research | T cells | Health aspects | HIV infection | Risk factors
Journal Article
The Journal of Infectious Diseases, ISSN 0022-1899, 6/2011, Volume 203, Issue 11, pp. 1637 - 1646
Background. Substantial morbidity occurs during the first year of antiretroviral therapy (ART) in persons with advanced human immunodeficiency virus (HIV)...
HIV/AIDS | Antiretrovirals | Hepatitis | HIV | RNA | Interleukins | Mortality | AIDS | Infections | Biological markers | Arts | MORTALITY | INFECTIOUS DISEASES | TUBERCULOSIS | MICROBIOLOGY | IMMUNOLOGY | IMMUNE RESTORATION DISEASE | INDIVIDUALS | CASE DEFINITIONS | INTERFERON-ALPHA | HIV-INFECTION | MORBIDITY | RECONSTITUTION INFLAMMATORY SYNDROME | PROGRESSION | Biomarkers - metabolism | HIV Infections - blood | Anti-Retroviral Agents - therapeutic use | Fibrin Fibrinogen Degradation Products - metabolism | Humans | Middle Aged | Risk Factors | Immune Reconstitution Inflammatory Syndrome - blood | Male | RNA, Viral - blood | Biomarkers - blood | Acquired Immunodeficiency Syndrome - drug therapy | Case-Control Studies | Disease Progression | Morbidity | C-Reactive Protein - metabolism | Immune Reconstitution Inflammatory Syndrome - virology | Interleukin-6 - blood | Adult | Female | HIV Infections - drug therapy | Acquired Immunodeficiency Syndrome - blood | Hyaluronic Acid - blood | Antiviral agents | Complications and side effects | Composition | Care and treatment | AIDS (Disease) | Causes of | HIV patients | Dosage and administration | Health aspects | Major and Brief Reports
HIV/AIDS | Antiretrovirals | Hepatitis | HIV | RNA | Interleukins | Mortality | AIDS | Infections | Biological markers | Arts | MORTALITY | INFECTIOUS DISEASES | TUBERCULOSIS | MICROBIOLOGY | IMMUNOLOGY | IMMUNE RESTORATION DISEASE | INDIVIDUALS | CASE DEFINITIONS | INTERFERON-ALPHA | HIV-INFECTION | MORBIDITY | RECONSTITUTION INFLAMMATORY SYNDROME | PROGRESSION | Biomarkers - metabolism | HIV Infections - blood | Anti-Retroviral Agents - therapeutic use | Fibrin Fibrinogen Degradation Products - metabolism | Humans | Middle Aged | Risk Factors | Immune Reconstitution Inflammatory Syndrome - blood | Male | RNA, Viral - blood | Biomarkers - blood | Acquired Immunodeficiency Syndrome - drug therapy | Case-Control Studies | Disease Progression | Morbidity | C-Reactive Protein - metabolism | Immune Reconstitution Inflammatory Syndrome - virology | Interleukin-6 - blood | Adult | Female | HIV Infections - drug therapy | Acquired Immunodeficiency Syndrome - blood | Hyaluronic Acid - blood | Antiviral agents | Complications and side effects | Composition | Care and treatment | AIDS (Disease) | Causes of | HIV patients | Dosage and administration | Health aspects | Major and Brief Reports
Journal Article
Blood, ISSN 0006-4971, 2009, Volume 114, Issue 4, pp. 751 - 752
In this issue of Blood, Beq and colleagues describe the massive yet transient exodus of T cells from peripheral blood to lymph nodes, skin, and gut lymphoid...
HEMATOLOGY | EXPANSION
HEMATOLOGY | EXPANSION
Journal Article
Blood, ISSN 0006-4971, 05/2010, Volume 115, Issue 18, pp. 3648 - 3649
Journal Article
Current Topics in Microbiology and Immunology, ISSN 0070-217X, 2018, Volume 417, pp. 157 - 180
The introduction of combination antiretroviral therapy (cART) in the 1990s has dramatically changed the course of HIV infection, decreasing the risk for both...
LYMPHATIC TISSUE FIBROSIS | HUMAN CYTOMEGALOVIRUS TROPISM | INCREASED RISK | PRIMARY HIV-1 INFECTION | CD4(+) T-CELLS | MICROBIOLOGY | ANTIRETROVIRAL THERAPY | IMMUNOLOGY | VIRUS TYPE-1 INFECTION | MICROBIAL TRANSLOCATION | RALTEGRAVIR INTENSIFICATION | VIRAL RESERVOIR
LYMPHATIC TISSUE FIBROSIS | HUMAN CYTOMEGALOVIRUS TROPISM | INCREASED RISK | PRIMARY HIV-1 INFECTION | CD4(+) T-CELLS | MICROBIOLOGY | ANTIRETROVIRAL THERAPY | IMMUNOLOGY | VIRUS TYPE-1 INFECTION | MICROBIAL TRANSLOCATION | RALTEGRAVIR INTENSIFICATION | VIRAL RESERVOIR
Journal Article
PLoS ONE, ISSN 1932-6203, 03/2012, Volume 7, Issue 3, p. e33948
Background: Limited knowledge exists on early HIV events that may inform preventive and therapeutic strategies. This study aims to characterize the earliest...
THERAPY | REPLICATION | RALTEGRAVIR | PERSISTENCE | MULTIDISCIPLINARY SCIENCES | IMMUNE ACTIVATION | DYNAMICS | RISK | RESTORATION | INTENSIFICATION | INTERRUPTION | HIV Infections - virology | Humans | Male | Treatment Outcome | CD4 Lymphocyte Count | Leukocytes, Mononuclear - virology | Intestines - immunology | Viral Load | Antiretroviral Therapy, Highly Active | CD4-Positive T-Lymphocytes - immunology | HIV Infections - immunology | HIV-1 - immunology | Receptors, CCR5 - metabolism | Intestines - virology | Adult | Female | HIV Infections - drug therapy | T-Lymphocytes - immunology | CD4-Positive T-Lymphocytes - virology | Virus Latency - immunology | Cytokines - blood | Medical research | Antiviral agents | Usage | RNA | Biological products industry | Development and progression | T cells | HIV (Viruses) | Anti-HIV agents | Highly active antiretroviral therapy | Medicine, Experimental | Health aspects | HIV infection | Laboratories | Viruses | Infections | Lymphocytes T | Medical diagnosis | Seeding | Efavirenz | Blood | Tenofovir | Restoration | Acquired immune deficiency syndrome--AIDS | Lymphocytes | Antiretroviral agents | Human immunodeficiency virus--HIV | Peripheral blood mononuclear cells | Remission | Armed forces | Drug therapy | Public health | Deoxyribonucleic acid--DNA | Emtricitabine | Antiretroviral drugs | CCR5 protein | Research & development--R&D | Ribonucleic acid--RNA | Disease control | CD4 antigen | Medicine | Depletion | Collaboration | Gene therapy | Research & development | Acquired immune deficiency syndrome | Deoxyribonucleic acid | Ribonucleic acid | AIDS | R&D | HIV | DNA | Human immunodeficiency virus
THERAPY | REPLICATION | RALTEGRAVIR | PERSISTENCE | MULTIDISCIPLINARY SCIENCES | IMMUNE ACTIVATION | DYNAMICS | RISK | RESTORATION | INTENSIFICATION | INTERRUPTION | HIV Infections - virology | Humans | Male | Treatment Outcome | CD4 Lymphocyte Count | Leukocytes, Mononuclear - virology | Intestines - immunology | Viral Load | Antiretroviral Therapy, Highly Active | CD4-Positive T-Lymphocytes - immunology | HIV Infections - immunology | HIV-1 - immunology | Receptors, CCR5 - metabolism | Intestines - virology | Adult | Female | HIV Infections - drug therapy | T-Lymphocytes - immunology | CD4-Positive T-Lymphocytes - virology | Virus Latency - immunology | Cytokines - blood | Medical research | Antiviral agents | Usage | RNA | Biological products industry | Development and progression | T cells | HIV (Viruses) | Anti-HIV agents | Highly active antiretroviral therapy | Medicine, Experimental | Health aspects | HIV infection | Laboratories | Viruses | Infections | Lymphocytes T | Medical diagnosis | Seeding | Efavirenz | Blood | Tenofovir | Restoration | Acquired immune deficiency syndrome--AIDS | Lymphocytes | Antiretroviral agents | Human immunodeficiency virus--HIV | Peripheral blood mononuclear cells | Remission | Armed forces | Drug therapy | Public health | Deoxyribonucleic acid--DNA | Emtricitabine | Antiretroviral drugs | CCR5 protein | Research & development--R&D | Ribonucleic acid--RNA | Disease control | CD4 antigen | Medicine | Depletion | Collaboration | Gene therapy | Research & development | Acquired immune deficiency syndrome | Deoxyribonucleic acid | Ribonucleic acid | AIDS | R&D | HIV | DNA | Human immunodeficiency virus
Journal Article
PLoS Pathogens, ISSN 1553-7366, 12/2014, Volume 10, Issue 12, p. e1004543
Mucosal Th17 cells play an important role in maintaining gut epithelium integrity and thus prevent microbial translocation. Chronic HIV infection is...
MICROBIOLOGY | ANTIRETROVIRAL THERAPY | PERIPHERAL LYMPHOCYTES | HUMAN-IMMUNODEFICIENCY-VIRUS | TYPE-1 INFECTION | VIROLOGY | LYMPHOID-TISSUE | LENTIVIRAL INFECTIONS | REGULATORY T-CELLS | GENE-EXPRESSION | MICROBIAL TRANSLOCATION | PARASITOLOGY | DISEASE PROGRESSION | Acute Disease | Anti-Retroviral Agents - therapeutic use | Th17 Cells - physiology | Prospective Studies | Humans | Middle Aged | Anti-Retroviral Agents - pharmacology | Male | Treatment Outcome | Biomarkers - blood | Immunity, Mucosal - drug effects | Intestinal Mucosa - physiology | HIV Infections - pathology | Time Factors | Biopsy | Adult | Female | HIV Infections - drug therapy | Immunity, Mucosal - physiology | HIV Infections - physiopathology | Colon, Sigmoid - pathology | Cytokines - blood | Intestinal Mucosa - pathology | Th17 Cells - pathology | Prevention | Antiviral agents | Dosage and administration | Host-virus relationships | Drug therapy | T cells | HIV infection | Health aspects | Antiretroviral drugs | Laboratories | Mortality | AIDS | Infections | Blood | Immunology | HIV | Acquired immune deficiency syndrome | Lymphocytes | Human immunodeficiency virus | Immune system
MICROBIOLOGY | ANTIRETROVIRAL THERAPY | PERIPHERAL LYMPHOCYTES | HUMAN-IMMUNODEFICIENCY-VIRUS | TYPE-1 INFECTION | VIROLOGY | LYMPHOID-TISSUE | LENTIVIRAL INFECTIONS | REGULATORY T-CELLS | GENE-EXPRESSION | MICROBIAL TRANSLOCATION | PARASITOLOGY | DISEASE PROGRESSION | Acute Disease | Anti-Retroviral Agents - therapeutic use | Th17 Cells - physiology | Prospective Studies | Humans | Middle Aged | Anti-Retroviral Agents - pharmacology | Male | Treatment Outcome | Biomarkers - blood | Immunity, Mucosal - drug effects | Intestinal Mucosa - physiology | HIV Infections - pathology | Time Factors | Biopsy | Adult | Female | HIV Infections - drug therapy | Immunity, Mucosal - physiology | HIV Infections - physiopathology | Colon, Sigmoid - pathology | Cytokines - blood | Intestinal Mucosa - pathology | Th17 Cells - pathology | Prevention | Antiviral agents | Dosage and administration | Host-virus relationships | Drug therapy | T cells | HIV infection | Health aspects | Antiretroviral drugs | Laboratories | Mortality | AIDS | Infections | Blood | Immunology | HIV | Acquired immune deficiency syndrome | Lymphocytes | Human immunodeficiency virus | Immune system
Journal Article
Current Opinion in HIV and AIDS, ISSN 1746-630X, 03/2016, Volume 11, Issue 2, pp. 191 - 200
PURPOSE OF REVIEWThis article explores new data from recent studies addressing the role of coinfections in immune activation in HIV-1-infected patients, with a...
immune reconstitution inflammatory syndrome | myeloid cells | innate immunity | biomarkers | tuberculosis | INTIMA-MEDIA THICKNESS | INFECTIOUS DISEASES | SIMPLEX-VIRUS TYPE-2 | OPPORTUNISTIC INFECTIONS | ANTIRETROVIRAL THERAPY | IMMUNOLOGY | HUMAN-IMMUNODEFICIENCY-VIRUS | CEREBROSPINAL-FLUID | HEPATITIS-C VIRUS | RECONSTITUTION INFLAMMATORY SYNDROME | T-CELL-ACTIVATION | CRYPTOCOCCAL MENINGITIS | HIV Infections - immunology | Immune Reconstitution Inflammatory Syndrome - physiopathology | Coinfection | Immune Reconstitution Inflammatory Syndrome - immunology | Humans | Immune Reconstitution Inflammatory Syndrome - complications | HIV Infections - complications | Biomarkers | HIV Infections - physiopathology | Immunity, Innate
immune reconstitution inflammatory syndrome | myeloid cells | innate immunity | biomarkers | tuberculosis | INTIMA-MEDIA THICKNESS | INFECTIOUS DISEASES | SIMPLEX-VIRUS TYPE-2 | OPPORTUNISTIC INFECTIONS | ANTIRETROVIRAL THERAPY | IMMUNOLOGY | HUMAN-IMMUNODEFICIENCY-VIRUS | CEREBROSPINAL-FLUID | HEPATITIS-C VIRUS | RECONSTITUTION INFLAMMATORY SYNDROME | T-CELL-ACTIVATION | CRYPTOCOCCAL MENINGITIS | HIV Infections - immunology | Immune Reconstitution Inflammatory Syndrome - physiopathology | Coinfection | Immune Reconstitution Inflammatory Syndrome - immunology | Humans | Immune Reconstitution Inflammatory Syndrome - complications | HIV Infections - complications | Biomarkers | HIV Infections - physiopathology | Immunity, Innate
Journal Article
The Lancet Infectious Diseases, ISSN 1473-3099, 02/2018, Volume 18, Issue 2, pp. 225 - 225
A 33-year-old woman, with HIV infection (CD4 count of 13 cells per μL; viral load of 1·2 x 106 copies per mL) and Mycobacterium tuberculosis diagnosed 2 months...
INFECTIOUS DISEASES | Nystagmus, Pathologic - pathology | Tuberculosis, Central Nervous System - diagnostic imaging | Brain - diagnostic imaging | Tuberculoma - diagnostic imaging | Humans | Tuberculosis, Central Nervous System - complications | Tuberculoma - complications | Magnetic Resonance Imaging | HIV Infections - complications | Brain - pathology | Adult | Female | Nystagmus, Pathologic - etiology | Tuberculoma | Medulla | Tuberculosis | Brain research | Human immunodeficiency virus--HIV | Nystagmus
INFECTIOUS DISEASES | Nystagmus, Pathologic - pathology | Tuberculosis, Central Nervous System - diagnostic imaging | Brain - diagnostic imaging | Tuberculoma - diagnostic imaging | Humans | Tuberculosis, Central Nervous System - complications | Tuberculoma - complications | Magnetic Resonance Imaging | HIV Infections - complications | Brain - pathology | Adult | Female | Nystagmus, Pathologic - etiology | Tuberculoma | Medulla | Tuberculosis | Brain research | Human immunodeficiency virus--HIV | Nystagmus
Journal Article
Current Opinion in HIV and AIDS, ISSN 1746-630X, 03/2016, Volume 11, Issue 2, pp. 129 - 130
Journal Article
PLoS ONE, ISSN 1932-6203, 2010, Volume 5, Issue 7, p. e11416
Background: Immune reconstitution inflammatory syndrome (IRIS) is reported widely in patients initiating antiretroviral therapy (ART). However, few studies are...
MORTALITY | ANTIRETROVIRAL THERAPY | HIV | INITIATION | MULTIDISCIPLINARY SCIENCES | CRYPTOCOCCAL MENINGITIS | Immune Reconstitution Inflammatory Syndrome - etiology | Anti-Retroviral Agents - therapeutic use | Humans | Middle Aged | Risk Factors | Anti-Retroviral Agents - adverse effects | Anti-Retroviral Agents - pharmacology | Proportional Hazards Models | Male | HIV - drug effects | Young Adult | Analysis of Variance | Time Factors | T-Lymphocyte Subsets - drug effects | Opportunistic Infections - drug therapy | Adult | Female | RNA, Viral - metabolism | Infection | Antiviral agents | Medical research | Highly active antiretroviral therapy | Tuberculosis | RNA | Immunotherapy | Medicine, Experimental | Mycoses | T cells | Health aspects | Risk factors | Corticoids | Antiretroviral drugs | Bacterial infections | Corticosteroids | Opportunist infection | Immune reconstitution | Lymphocytes T | Inflammation | Infections | Regression analysis | Ribonucleic acid--RNA | Medical diagnosis | Patients | Antiretroviral therapy | CD4 antigen | Fungi | Immunosuppression | Randomization | Acquired immune deficiency syndrome--AIDS | Antiretroviral agents | Human immunodeficiency virus--HIV | Acquired immune deficiency syndrome | Ribonucleic acid | AIDS | Human immunodeficiency virus
MORTALITY | ANTIRETROVIRAL THERAPY | HIV | INITIATION | MULTIDISCIPLINARY SCIENCES | CRYPTOCOCCAL MENINGITIS | Immune Reconstitution Inflammatory Syndrome - etiology | Anti-Retroviral Agents - therapeutic use | Humans | Middle Aged | Risk Factors | Anti-Retroviral Agents - adverse effects | Anti-Retroviral Agents - pharmacology | Proportional Hazards Models | Male | HIV - drug effects | Young Adult | Analysis of Variance | Time Factors | T-Lymphocyte Subsets - drug effects | Opportunistic Infections - drug therapy | Adult | Female | RNA, Viral - metabolism | Infection | Antiviral agents | Medical research | Highly active antiretroviral therapy | Tuberculosis | RNA | Immunotherapy | Medicine, Experimental | Mycoses | T cells | Health aspects | Risk factors | Corticoids | Antiretroviral drugs | Bacterial infections | Corticosteroids | Opportunist infection | Immune reconstitution | Lymphocytes T | Inflammation | Infections | Regression analysis | Ribonucleic acid--RNA | Medical diagnosis | Patients | Antiretroviral therapy | CD4 antigen | Fungi | Immunosuppression | Randomization | Acquired immune deficiency syndrome--AIDS | Antiretroviral agents | Human immunodeficiency virus--HIV | Acquired immune deficiency syndrome | Ribonucleic acid | AIDS | Human immunodeficiency virus
Journal Article
Current opinion in HIV and AIDS, ISSN 1746-630X, 3/2016, Volume 11, Issue 2, pp. 191 - 200
Journal Article